Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data
ConclusionLCD and associated rapid metabolism of non-clozapine antipsychotics is frequent before starting clozapine treatment. For olanzapine and quetiapine, this is associated with significantly increased risk of having subtherapeutic concentrations. (Source: CNS Drugs)
Source: CNS Drugs - April 18, 2024 Category: Neurology Source Type: research
Vitreous humor in the forensic toxicology of quetiapine and its metabolites
ConclusionThe results of the study indicate the usefulness of vitreous humor in toxicological analysis for the determination of these substances, especially when the traditional biological materials are not available. The levels of quetiapine and its metabolites in vitreous humor as well as the vitreous humor to blood concentration ratios can provide important information for a more thorough toxicological investigation of forensic cases. (Source: Forensic Toxicology)
Source: Forensic Toxicology - April 14, 2024 Category: Forensic Medicine Source Type: research
Antipsychotic prescribing: national findings of children and adolescents attending mental health services in Ireland
We described the frequency of antipsychotic medication, medication type, target condition, target symptom and medication doses. We used multivariable logistic regression, adjusted with available co-variates to assess the association of being presc ribed an antipsychotic medication. Twelve percentage (n = 437) were prescribed an antipsychotic and 16–17-years (n = 211, 48.3%) was the most common age category. The commonest reason for prescribing an antipsychotic was target symptoms (i.e., off-label use) (n = 329; 75.%) and of thes e symptoms, agitation (n = 77/329; 25%) and irritability (56/239; 25%) were t...
Source: European Child and Adolescent Psychiatry - April 12, 2024 Category: Psychiatry Source Type: research
Mucoadhesive chitosan-poly (lactic-co-glycolic acid) nanoparticles for intranasal delivery of quetiapine - Development & amp; characterization in physiologically relevant 3D tissue models
Int J Biol Macromol. 2024 Apr 8:131491. doi: 10.1016/j.ijbiomac.2024.131491. Online ahead of print.ABSTRACTQuetiapine hemifumarate (QF) delivery to the CNS via conventional formulations is challenging due to poor solubility and lower oral bioavailability (9 %). Similarly, many other second-generation antipsychotics, such as olanzapine, clozapine, and paliperidone, have also shown low oral bioavailability of <50 %. Hence, the present work was intended to formulate QF-loaded biodegradable PLGA-NPs with appropriate surface charge modification through poloxamer-chitosan and investigate its targeting potential on RPMI-2650 c...
Source: International Journal of Biological Macromolecules - April 10, 2024 Category: Biochemistry Authors: Dnyandev G Gadhave Mural Quadros Akanksha R Ugale Mimansa Goyal Seyoum Ayehunie Vivek Gupta Source Type: research
Mucoadhesive chitosan-poly (lactic-co-glycolic acid) nanoparticles for intranasal delivery of quetiapine - Development & amp; characterization in physiologically relevant 3D tissue models
Int J Biol Macromol. 2024 Apr 8:131491. doi: 10.1016/j.ijbiomac.2024.131491. Online ahead of print.ABSTRACTQuetiapine hemifumarate (QF) delivery to the CNS via conventional formulations is challenging due to poor solubility and lower oral bioavailability (9 %). Similarly, many other second-generation antipsychotics, such as olanzapine, clozapine, and paliperidone, have also shown low oral bioavailability of <50 %. Hence, the present work was intended to formulate QF-loaded biodegradable PLGA-NPs with appropriate surface charge modification through poloxamer-chitosan and investigate its targeting potential on RPMI-2650 c...
Source: International Journal of Biological Macromolecules - April 10, 2024 Category: Biochemistry Authors: Dnyandev G Gadhave Mural Quadros Akanksha R Ugale Mimansa Goyal Seyoum Ayehunie Vivek Gupta Source Type: research
Antipsychotic drugs in first-episode psychosis: A target trial emulation in the FEP-CAUSAL Collaboration
Am J Epidemiol. 2024 Apr 3:kwae029. doi: 10.1093/aje/kwae029. Online ahead of print.ABSTRACTGood adherence to antipsychotic therapy helps prevent relapses in First Episode Psychosis (FEP). We used data from the FEP-CAUSAL Collaboration, an international consortium of observational cohorts to emulate a target trial comparing antipsychotics with treatment discontinuation as the primary outcome. Other outcomes included all-cause hospitalization. We benchmarked our results to estimates from EUFEST, a randomized trial conducted in the 2000s. We included 1097 patients with a psychotic disorder and less than 2 years since psychos...
Source: Am J Epidemiol - April 5, 2024 Category: Epidemiology Authors: Alejandro G Szmulewicz Gonzalo Mart ínez-Alés Roger Logan Maria Ferrara Christian Kelly Diane Fredrikson Juan Gago Sarah Conderino Covadonga M D íaz-Caneja Joaqu ín Galvañ Lorna Thorpe Vinod Srihari Lakshmi Yatham Deepak K Sarpal Ann K Shinn Celso Ar Source Type: research
Antipsychotic drugs in first-episode psychosis: A target trial emulation in the FEP-CAUSAL Collaboration
Am J Epidemiol. 2024 Apr 3:kwae029. doi: 10.1093/aje/kwae029. Online ahead of print.ABSTRACTGood adherence to antipsychotic therapy helps prevent relapses in First Episode Psychosis (FEP). We used data from the FEP-CAUSAL Collaboration, an international consortium of observational cohorts to emulate a target trial comparing antipsychotics with treatment discontinuation as the primary outcome. Other outcomes included all-cause hospitalization. We benchmarked our results to estimates from EUFEST, a randomized trial conducted in the 2000s. We included 1097 patients with a psychotic disorder and less than 2 years since psychos...
Source: Am J Epidemiol - April 5, 2024 Category: Epidemiology Authors: Alejandro G Szmulewicz Gonzalo Mart ínez-Alés Roger Logan Maria Ferrara Christian Kelly Diane Fredrikson Juan Gago Sarah Conderino Covadonga M D íaz-Caneja Joaqu ín Galvañ Lorna Thorpe Vinod Srihari Lakshmi Yatham Deepak K Sarpal Ann K Shinn Celso Ar Source Type: research
Antipsychotic drugs in first-episode psychosis: A target trial emulation in the FEP-CAUSAL Collaboration
Am J Epidemiol. 2024 Apr 3:kwae029. doi: 10.1093/aje/kwae029. Online ahead of print.ABSTRACTGood adherence to antipsychotic therapy helps prevent relapses in First Episode Psychosis (FEP). We used data from the FEP-CAUSAL Collaboration, an international consortium of observational cohorts to emulate a target trial comparing antipsychotics with treatment discontinuation as the primary outcome. Other outcomes included all-cause hospitalization. We benchmarked our results to estimates from EUFEST, a randomized trial conducted in the 2000s. We included 1097 patients with a psychotic disorder and less than 2 years since psychos...
Source: Am J Epidemiol - April 5, 2024 Category: Epidemiology Authors: Alejandro G Szmulewicz Gonzalo Mart ínez-Alés Roger Logan Maria Ferrara Christian Kelly Diane Fredrikson Juan Gago Sarah Conderino Covadonga M D íaz-Caneja Joaqu ín Galvañ Lorna Thorpe Vinod Srihari Lakshmi Yatham Deepak K Sarpal Ann K Shinn Celso Ar Source Type: research
Clozapine, LAIs Found Effective in Patients With First-Episode Psychosis and Cannabis Use Disorder
Individuals with first-episode psychosis (FEP) and cannabis use disorder who were prescribed any antipsychotic were significantly less likely to be hospitalized for psychosis than similar patients who did not receive an antipsychotic, according to areport inSchizophrenia Bulletin.Clozapine and long-acting injectable (LAI) formulations of risperidone, aripiprazole, and paliperidone were the most effective medications at preventing relapse and hospitalization due to psychosis. Clozapine was also most effective at preventing hospitalization due to substance use.Alexander Denissoff, M.D., of the University of Turku, Finland, a...
Source: Psychiatr News - April 3, 2024 Category: Psychiatry Tags: cannabis Finland first-episode psychosis health registries hospitalization relapse schizophrenia substance use disorder Source Type: research
Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium: Randomized Controlled Trial
ConclusionsQuetiapine may be equally as effective as haloperidol in treating the symptoms of hyperactive delirium in critically ill patients, with no mortality benefit. (Source: Neurocritical Care)
Source: Neurocritical Care - April 1, 2024 Category: Neurology Source Type: research
Minor tranquillizers for short-term treatment of newly onset symptoms of anxiety and distress: a systematic review with network meta-analysis of randomized trials
AbstractUnspecific symptoms of anxiety and distress are frequently encountered in patients in both general practice and acute psychiatric services. Minor tranquillizers may be a treatment option when non-pharmacological interventions are insufficient or unavailable. We conducted a systematic review with network meta-analysis of the evidence for short-term (1 –4 weeks) pharmacological treatment of newly onset symptoms of anxiety and distress. We searched the PsycInfo, MEDLINE, EMBASE and Cochrane Library databases and extracted data following a predefined hierarchy of outcomes. We assessed risk of bias using the Cochrane...
Source: European Archives of Psychiatry and Clinical Neuroscience - April 1, 2024 Category: Neuroscience Source Type: research
The influence of concomitant antidepressant and antipsychotic medication on antidepressant effect and seizure duration of electroconvulsive therapy
ConclusionTaken together, our study underlines that concomitant psychotropic medication while doing electroconvulsive therapy does not bare the risk of prolonged seizure duration or does it reduce the effectiveness of ECT. To the best of our knowledge, this study is the first to examine the effect of treatment with antidepressants in combination with antipsychotics while doing ECT. In light of our results, this combination therapy is safe and effective. Bearing in mind the delay in onset of antidepressant action of medication and the importance of antidepressant medication for relapse prevention, this study further support...
Source: Frontiers in Psychiatry - March 18, 2024 Category: Psychiatry Source Type: research
Serum S100B Protein and White Matter Changes in Schizophrenia before and after Medication
Brain Res Bull. 2024 Mar 12:110927. doi: 10.1016/j.brainresbull.2024.110927. Online ahead of print.ABSTRACTSchizophrenia patients have abnormalities in white matter (WM) integrity in brain regions. S100B has been shown to be a marker protein for glial cells. The atypical antipsychotics have neuroprotective effects on the brain. It is not clear whether antipsychotics can induce S100B changes and improve symptoms by protecting oligodendrocytes. To investigate WM and S100B changes and associations and determine the effect of quetiapine on WM and S100B in schizophrenia patients, we determined serum S100B levels with solid phas...
Source: Brain Research - March 14, 2024 Category: Neurology Authors: Han Shi Yan Zhang YongFeng Yang HaiSan Zhang WenQiang Li ZhaoXi Zhong LuXian Lv Source Type: research
Serum S100B Protein and White Matter Changes in Schizophrenia before and after Medication
Brain Res Bull. 2024 Mar 12:110927. doi: 10.1016/j.brainresbull.2024.110927. Online ahead of print.ABSTRACTSchizophrenia patients have abnormalities in white matter (WM) integrity in brain regions. S100B has been shown to be a marker protein for glial cells. The atypical antipsychotics have neuroprotective effects on the brain. It is not clear whether antipsychotics can induce S100B changes and improve symptoms by protecting oligodendrocytes. To investigate WM and S100B changes and associations and determine the effect of quetiapine on WM and S100B in schizophrenia patients, we determined serum S100B levels with solid phas...
Source: Brain Research Bulletin - March 14, 2024 Category: Neurology Authors: Han Shi Yan Zhang YongFeng Yang HaiSan Zhang WenQiang Li ZhaoXi Zhong LuXian Lv Source Type: research
Serum S100B Protein and White Matter Changes in Schizophrenia before and after Medication
Brain Res Bull. 2024 Mar 12:110927. doi: 10.1016/j.brainresbull.2024.110927. Online ahead of print.ABSTRACTSchizophrenia patients have abnormalities in white matter (WM) integrity in brain regions. S100B has been shown to be a marker protein for glial cells. The atypical antipsychotics have neuroprotective effects on the brain. It is not clear whether antipsychotics can induce S100B changes and improve symptoms by protecting oligodendrocytes. To investigate WM and S100B changes and associations and determine the effect of quetiapine on WM and S100B in schizophrenia patients, we determined serum S100B levels with solid phas...
Source: Brain Research Bulletin - March 14, 2024 Category: Neurology Authors: Han Shi Yan Zhang YongFeng Yang HaiSan Zhang WenQiang Li ZhaoXi Zhong LuXian Lv Source Type: research
